BRCA1 and neoplasm: One of the best described mechanisms both in vivo and in clinical practice is the reversion mutation of BRCA. Several studies have identified tumor-specific BRCA1 or BRCA2 secondary mutations in PARPi-resistant BC cells, both in tissue and in ctDNA [62,63,64].